These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19747967)

  • 1. Prediction of drug particle size and content uniformity in low-dose solid dosage forms.
    Huang CY; Sherry Ku M
    Int J Pharm; 2010 Jan; 383(1-2):70-80. PubMed ID: 19747967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetry effect of particle size distribution on content uniformity and over-potency risk in low-dose solid drugs.
    Huang CY; Ku MS
    J Pharm Sci; 2010 Oct; 99(10):4351-62. PubMed ID: 20737638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Content uniformity acceptance limit for a validation batch--suppositories, transdermal systems, and inhalations.
    Senderak ET
    Drug Dev Ind Pharm; 2009 Jun; 35(6):735-7. PubMed ID: 19514989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminatory power of the different requirements for uniformity of dosage units in the European pharmacopoeia.
    Limberg J; Savsek M
    Pharmeur Sci Notes; 2006 Dec; 2006(2):45-8. PubMed ID: 17691214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Milling of agglomerates in an impact mill.
    Verheezen JJ; van der Voort Maarschalk K; Faassen F; Vromans H
    Int J Pharm; 2004 Jun; 278(1):165-72. PubMed ID: 15158958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle size limits to meet USP content uniformity criteria for tablets and capsules.
    Rohrs BR; Amidon GE; Meury RH; Secreast PJ; King HM; Skoug CJ
    J Pharm Sci; 2006 May; 95(5):1049-59. PubMed ID: 16552749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confocal Raman microscopy to probe content uniformity of a lipid based powder for inhalation: a quality by design approach.
    Schoenherr C; Haefele T; Paulus K; Francese G
    Eur J Pharm Sci; 2009 Aug; 38(1):47-54. PubMed ID: 19501161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution.
    Tinke AP; Vanhoutte K; De Maesschalck R; Verheyen S; De Winter H
    J Pharm Biomed Anal; 2005 Oct; 39(5):900-7. PubMed ID: 16023816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uniformity of dosage units--comparative study of methods and specifications between Eur. Pharm. 3rd and USP 23.
    Martins JM; Farinha A
    J Pharm Biomed Anal; 1998 Dec; 18(4-5):487-95. PubMed ID: 9919948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appeal for uniformity in the dosage formulations.
    Radhakrishna H
    J Assoc Physicians India; 1998 Jun; 46(6):579. PubMed ID: 11273276
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence studies for complex active ingredients and dosage forms.
    Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R
    AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triboelectrification of pharmaceutical powders by particle impact.
    Watanabe H; Ghadiri M; Matsuyama T; Ding YL; Pitt KG; Maruyama H; Matsusaka S; Masuda H
    Int J Pharm; 2007 Apr; 334(1-2):149-55. PubMed ID: 17141989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: a noninvasive off-line calibration approach.
    Sulub Y; Wabuyele B; Gargiulo P; Pazdan J; Cheney J; Berry J; Gupta A; Shah R; Wu H; Khan M
    J Pharm Biomed Anal; 2009 Jan; 49(1):48-54. PubMed ID: 19027256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of NIR in early stage formulation development. Part I. Semi-quantitative blend uniformity and content uniformity analyses by reflectance NIR without calibration models.
    Li W; Bashai-Woldu A; Ballard J; Johnson M; Agresta M; Rasmussen H; Hu S; Cunningham J; Winstead D
    Int J Pharm; 2007 Aug; 340(1-2):97-103. PubMed ID: 17467204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective dose scaling factors for use with uranium series cascade impactor data: a reassessment using the IMBA code.
    Kim KP; Wu CY; Birky BK; Bolch WE
    Health Phys; 2006 Oct; 91(4):331-7. PubMed ID: 16966876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A first-principles model for prediction of product dose uniformity based on drug substance particle size distribution.
    Hilden J; Schrad M; Kuehne-Willmore J; Sloan J
    J Pharm Sci; 2012 Jul; 101(7):2364-71. PubMed ID: 22504845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.